![Cancers | Free Full-Text | Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity Cancers | Free Full-Text | Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity](https://www.mdpi.com/cancers/cancers-14-03226/article_deploy/html/images/cancers-14-03226-g001.png)
Cancers | Free Full-Text | Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Retrospective Comparison Focusing on Pulmonary Toxicity
![Olaparib + durvalumab + tremelimumab combination therapy dosing schedule | Download Scientific Diagram Olaparib + durvalumab + tremelimumab combination therapy dosing schedule | Download Scientific Diagram](https://www.researchgate.net/publication/343564074/figure/fig2/AS:962782438641664@1606556629165/Olaparib-durvalumab-tremelimumab-combination-therapy-dosing-schedule.png)
Olaparib + durvalumab + tremelimumab combination therapy dosing schedule | Download Scientific Diagram
![Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis](https://www.frontiersin.org/files/Articles/602185/fonc-10-602185-HTML-r1/image_m/fonc-10-602185-g001.jpg)
Frontiers | First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis
![A) Real-world PFS and (B) OS according to durvalumab dosing schedule.... | Download Scientific Diagram A) Real-world PFS and (B) OS according to durvalumab dosing schedule.... | Download Scientific Diagram](https://www.researchgate.net/publication/359917383/figure/fig1/AS:1151724886732801@1651604019022/A-Real-world-PFS-and-B-OS-according-to-durvalumab-dosing-schedule-Data-cutoff-was.jpg)
A) Real-world PFS and (B) OS according to durvalumab dosing schedule.... | Download Scientific Diagram
![Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study - The Lancet Oncology Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study - The Lancet Oncology](https://www.thelancet.com/cms/attachment/5d2cbbb0-1f77-4f27-8b4e-ea5f0adb5669/gr1_lrg.jpg)
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study - The Lancet Oncology
![Astrazeneca Imfinzi (Durvalumab), Dosage Form: Injection, Single Use Vial at Rs 48000/vial in Patiala Astrazeneca Imfinzi (Durvalumab), Dosage Form: Injection, Single Use Vial at Rs 48000/vial in Patiala](https://5.imimg.com/data5/SELLER/Default/2023/3/HC/DJ/PH/184803378/imfinzi-durvalumab--500x500.jpg)
Astrazeneca Imfinzi (Durvalumab), Dosage Form: Injection, Single Use Vial at Rs 48000/vial in Patiala
![IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer](https://storage.googleapis.com/afs-prod/media/439befbd5afc359436c102d1288d7492/1000.jpeg)
IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
![DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment | BMC Cancer | Full Text DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment | BMC Cancer | Full Text](https://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs12885-018-4764-0/MediaObjects/12885_2018_4764_Fig2_HTML.png)
DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment | BMC Cancer | Full Text
![AstraZeneca's Imfinzi (durvalumab) approved in the US for new four-week 1,500mg fixed-dosing option | EuropaWire.eu | The European Union's press release distribution & newswire service AstraZeneca's Imfinzi (durvalumab) approved in the US for new four-week 1,500mg fixed-dosing option | EuropaWire.eu | The European Union's press release distribution & newswire service](https://news.europawire.eu/wp-content/uploads/2020/11/AstraZeneca%E2%80%99s-Imfinzi-durvalumab-approved-in-the-US-for-new-four-week-1500mg-fixed-dosing-option.png)
AstraZeneca's Imfinzi (durvalumab) approved in the US for new four-week 1,500mg fixed-dosing option | EuropaWire.eu | The European Union's press release distribution & newswire service
![Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/82f91f32-14cf-4084-808a-291e06fbe245/gr1_lrg.gif)